NCT06500065 68Ga-DOTATATE PET/CT for the Diagnosis of Soft Tissue Sarcomas
| NCT ID | NCT06500065 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ohio State University Comprehensive Cancer Center |
| Condition | Soft Tissue Sarcoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2024-09-30 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2024-09-30 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This trial studies how well 68Ga-DOTATATE digital PET/CT work in diagnosing soft tissue sarcoma. 68Ga-DOTATATE is a radiotracer that may improve image quality of PET imaging. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, in the case of this research, 68Ga-DOTATATE. CT images provide an exact outline of organs and potential inflammatory tissue where it occurs in patient's body. 68Ga-DOTATATE digital PET/CT may work better in imaging patients with soft tissue sarcomas.
Eligibility Criteria
Inclusion Criteria: * Patients \>= 18 years of age * Patients diagnosed with any stage of soft tissue sarcomas candidates for systemic therapies * Patients with one standard of care PET/CT scan up to 30 days before enrollment at the Ohio State University facilities. Exclusion Criteria: * Hypersensitivity to somatostatin or similar peptides * Somatostatin long-acting analog in the past 6 months * Patients who are pregnant or lactating * Patients who are currently incarcerated * Patients with acute infections * Inability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.) * Patients exceeding the weight limitations of the scanner or are not able to enter the bore of the dPET/CT scanner due to body mass index (BMI)
Contact & Investigator
Gabriel R Tinoco Suarez
PRINCIPAL INVESTIGATOR
Ohio State University Comprehensive Cancer Center
Frequently Asked Questions
Who can join the NCT06500065 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Soft Tissue Sarcoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06500065 currently recruiting?
Yes, NCT06500065 is actively recruiting participants. Visit ClinicalTrials.gov or contact Ohio State University Comprehensive Cancer Center to inquire about joining.
Where is the NCT06500065 trial being conducted?
This trial is being conducted at Columbus, United States.
Who is sponsoring the NCT06500065 clinical trial?
NCT06500065 is sponsored by Ohio State University Comprehensive Cancer Center. The principal investigator is Gabriel R Tinoco Suarez at Ohio State University Comprehensive Cancer Center. The trial plans to enroll 30 participants.